Acumen Pharmaceuticals (ABOS) Stock Statistics & Valuation Metrics

Acumen Pharmaceuticals has a market cap or net worth of $15.64M. The enterprise value is $108.26M.

Market Cap

$15.64M

Enterprise Value

$108.26M

Acumen Pharmaceuticals has 72,327,320 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

72,327,320

Owned by Insiders

32.71%

Owned by Institutions

11.97%

Acumen Pharmaceuticals’s return on equity (ROE) is -1.72 and return on invested capital (ROIC) is -121.71%.

Return on Equity (ROE)

-1.72

Return on Assets (ROA)

-0.99

Return on Invested Capital (ROIC)

-121.71%

Return on Capital Employed (ROCE)

-1.33

Revenue Per Employee

0

Profits Per Employee

-1.99M

Employee Count

61

Asset Turnover

0.00

Inventory Turnover

0.00

The current PE Ratio of Acumen Pharmaceuticals is -0.14. Acumen Pharmaceuticals’s PEG ratio is -0.00.

PE Ratio

-0.14

PS Ratio

0.00

PB Ratio

0.45

Price to FCF

-0.18

Price to Operating Cash Flow

-0.18

PEG Ratio

-0.00

In the last 12 months, Acumen Pharmaceuticals had revenue of 0 and earned -121.33M in profits. Earnings per share was -2.00.

Revenue

0

Gross Profit

0

Operating Income

-123.83M

Pretax Income

-121.33M

Net Income

-121.33M

EBITDA

-116.93M

Earnings Per Share (EPS)

-2.00

In the last 12 months, operating cash flow was -87.95M and capital expenditures 0, giving a free cash flow of -87.95M billion.

Operating Cash Flow

-87.95M

Free Cash Flow

-87.95M

Free Cash Flow per Share

-1.22

Acumen Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-574.41%

Earnings Yield

-679.03%

Beta

2.47

52-Week Price Change

-89.51%

50-Day Moving Average

2.29

200-Day Moving Average

2.50

Relative Strength Index (RSI)

20.83

Average Volume (3m)

2.38M

Acumen Pharmaceuticals upcoming earnings date is Mar 29, 2027, TBA (Not Confirmed).

Last Earnings Date

Oct 26, 2026

Next Earnings Date

Mar 29, 2027

Ex-Dividend Date

―

Acumen Pharmaceuticals as a current ratio of 4.07, with Debt / Equity ratio of 44.46%

Current Ratio

4.07

Quick Ratio

4.07

Debt to Market Cap

0.24

Net Debt to EBITDA

0.19

Interest Coverage Ratio

-29.32

In the past 12 months, Acumen Pharmaceuticals has paid 0 in taxes.

Income Tax

0

Effective Tax Rate

0.00

Acumen Pharmaceuticals EV to EBITDA ratio is 0.12, with an EV/FCF ratio of 0.13.

EV to Sales

0.00

EV to EBITDA

0.12

EV to Free Cash Flow

0.13

EV to Operating Cash Flow

0.13

Acumen Pharmaceuticals has $78.60M in cash and marketable securities with $26.27M in debt, giving a net cash position of $52.33M billion.

Cash & Marketable Securities

$78.60M

Total Debt

$26.27M

Net Cash

$52.33M

Net Cash Per Share

$0.72

Tangible Book Value Per Share

$0.48

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin

0.00%

Operating Margin

0.00%

Pretax Margin

0.00%

Net Profit Margin

0.00%

EBITDA Margin

0.00%

EBIT Margin

0.00%

The average price target for Acumen Pharmaceuticals is $1.00, which is 11.43% higher than the current price. The consensus rating is Neutral

Price Target

$1.00

Price Target Upside

369.48% Upside

Analyst Consensus

Neutral

Analyst Count

6

Revenue Growth Forecast

―

EPS Growth Forecast

29.92%

Smart Score

―

AI Score

41